GSK and SK bioscience's COVID vaccine submitted for South Korea approval

1 minute read

Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. REUTERS/Matthew Childs/File Photo

Register now for FREE unlimited access to Reuters.com

April 29 (Reuters) - GlaxoSmithKline's (GSK) (GSK.L) COVID-19 vaccine candidate developed with SK bioscience (302440.KS) has been submitted for regulatory approval in South Korea after positive positive Phase III clinical data, the British drugmaker said on Friday.

GSK said that SK bioscience will also apply to the World Health Organization (WHO) for emergency use listing and seek authorisations at individual regulatory agencies around the world.

The company said an extended clinical trial is planned to test the vaccine's effectiveness against the Omicron variant of the virus.

Register now for FREE unlimited access to Reuters.com
Reporting by Miyoung Kim Editing by David Goodman

Our Standards: The Thomson Reuters Trust Principles.